SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the design, manufacture, and launch of rockets and spacecrafts. It provides satellite communication services. The company was founded by Elon Reeve Musk on March 14, 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Investors are actively debating the long-term viability of the SpaceX IPO, with bulls highlighting the company's ambitious infrastructure goals and potential for future index inclusion, while bears warn of extreme overvaluation and persistent cash burn. Community discourse remains polarized between those viewing this as a generational buy and others cautioning against significant downside risk as the initial hype meets real-world fundamentals.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as investors weigh potential antitrust hurdles, including reports of state-level lawsuits, against the company's efforts to finalize its major acquisition of Warner Bros. Discovery. While some community members remain focused on regulatory timelines and the strategic integration of content, others are actively debating the potential impact on share price and the long-term viability of the combined entity.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing heavy volatility and downward pressure as capital rotates into the high-profile SpaceX IPO, creating a liquidity vacuum across the space sector. Despite the selling, community members remain focused on the upcoming launch of new satellites as a critical catalyst to validate long-term growth and spark a recovery.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Investors are actively debating whether Destiny Tech 100 remains a viable proxy for SpaceX exposure or a value trap following the recent share offering and the impending public debut of the underlying holding. While some community members view the current volatility as a discount opportunity before subsequent Anthropic and OpenAI IPOs, others remain skeptical, citing concerns over management's dilution strategy and a potential decline in the fund's scarcity premium.

Entrepreneurshares Series Trust - ERShares Private-Public Crossover ETF

Investors are expressing frustration over the ETF's lack of upward momentum despite its concentrated holding in SpaceX, with many in the community debating the impact of the fund's SPV-based valuation structure versus direct equity exposure. Discussions focus on whether the market is discounting the fund's private asset holdings ahead of a broader public launch or if the current price action reflects concerns regarding transparency and the fund's long-term growth potential.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares are experiencing significant volatility and trading volume following reports that the streaming platform is engaged in early-stage buyout discussions with a major media company. While investors are debating the credibility of these rumors and the potential valuation, the community is actively discussing the company's long-term potential in the ad-supported streaming market and the implications of a possible consolidation deal.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

ARS Pharmaceuticals is trending as its competitor Aquestive Therapeutics faces a regulatory setback regarding their Anaphylm treatment, solidifying SPRY's position as the sole provider of an FDA-approved, needle-free epinephrine solution. Investors are actively discussing the potential for a significant short squeeze given the stock's high short interest and the removal of near-term competitive pressure.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as the community highlights the stock's role in the critical semiconductor supply chain, specifically through its expanding advanced packaging and testing infrastructure in Arizona. Investors are actively discussing the "Z-Axis Trade," a theme focused on packaging companies that are essential for scaling AI compute, with many noting a broad-based rotation into these manufacturers as they hit new 52-week highs.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is capturing attention as investors rotate toward quality-tilted, dividend-growth strategies to balance portfolio volatility. The community remains focused on long-term accumulation, with ongoing discussions emphasizing the fund's role as a core defensive anchor that provides income stability through market cycles.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery shareholders have officially approved the $110 billion merger with Paramount Skydance, a move that is reshaping the media landscape despite ongoing antitrust scrutiny and significant opposition from Hollywood creators concerned about industry consolidation. Investors are closely monitoring the regulatory path to completion while actively debating the valuation of the deal against the broader competitive pressures from streaming giants like Netflix.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study

Kymera shares climb after patient dosing begins in a phase I KT-485 study, triggering a $20 million milestone payment from Sanofi.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

Canaccord Genuity Group Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)

Canaccord Genuity Group started coverage on Kymera Therapeutics in a report on Wednesday. They issued a 'buy' rating and a $106.00 target price for the company...

UBS Group AG Buys 88,314 Shares of Kymera Therapeutics, Inc. $KYMR

UBS Group AG lifted its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 13.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and...

Q2 EPS Estimate for Kymera Therapeutics Boosted by Analyst

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a report released on Monday, May 4th. HC Wainwright analyst A. Fein now expects that the company will post earnings pe...

Jennison Associates LLC Decreases Stock Position in Kymera Therapeutics, Inc. $KYMR

Jennison Associates LLC lowered its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 51.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 496,665 shares of the company's sto...

Kymera Therapeutics (NASDAQ:KYMR) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration 

Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.

Kymera Therapeutics (NASDAQ:KYMR) Posts Earnings Results, Beats Expectations By $0.18 EPS

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.71) earnings per share for the quarter, topping analysts' consensus...

Kymera Therapeutics Q1 Earnings Call Highlights

Kymera Therapeutics (NASDAQ:KYMR) highlighted progress across its clinical-stage pipeline and provided a financial update during its first-quarter 2026 results call, with executives emphasizing...

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.72	--	--	N/A
Q1 '26	-$0.88	-$0.71	19.37%	BEAT
Q4 '25	-$0.78	-$0.97	-23.78%	MISSED
Q3 '25	-$0.76	-$0.94	-23.44%	MISSED
Q2 '25	-$0.81	-$0.95	-17.28%	MISSED

KYMRKymera Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest KYMR News